CEL-SCI (NYSE:CVM) Downgraded to Sell Rating by StockNews.com

StockNews.com lowered shares of CEL-SCI (NYSE:CVM) from a hold rating to a sell rating in a research note released on Wednesday.

CEL-SCI Stock Down 3.5 %

Shares of CEL-SCI stock opened at $0.62 on Wednesday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.18 and a current ratio of 0.64. CEL-SCI has a 52-week low of $0.54 and a 52-week high of $3.23. The company’s 50 day moving average price is $0.93 and its 200-day moving average price is $1.13. The stock has a market capitalization of $39.75 million, a price-to-earnings ratio of -1.07 and a beta of 0.69.

Institutional Trading of CEL-SCI

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in CEL-SCI by 5.5% during the 1st quarter. Vanguard Group Inc. now owns 2,193,327 shares of the company’s stock valued at $4,189,000 after purchasing an additional 113,703 shares during the last quarter. Plotkin Financial Advisors LLC purchased a new position in shares of CEL-SCI during the third quarter valued at approximately $98,000. Thoroughbred Financial Services LLC raised its holdings in shares of CEL-SCI by 140.9% during the second quarter. Thoroughbred Financial Services LLC now owns 136,761 shares of the company’s stock valued at $158,000 after acquiring an additional 80,001 shares in the last quarter. Geode Capital Management LLC lifted its stake in CEL-SCI by 9.6% in the third quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock worth $650,000 after acquiring an additional 53,879 shares during the period. Finally, Calton & Associates Inc. bought a new stake in CEL-SCI in the third quarter valued at $50,000. 12.08% of the stock is currently owned by hedge funds and other institutional investors.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.